{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:26:46Z","timestamp":1786606006385,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiotoxicity associated with antineoplastic therapies remains an important clinical challenge in modern oncology. Early identification of subclinical cardiac injury may improve cardiovascular surveillance and long-term outcomes in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective observational cohort study included 90 adult patients with breast cancer, lymphoma, or lung cancer receiving potentially cardiotoxic therapy. Patients with clinically manifest heart failure, severe arrhythmias, advanced renal disease, recent acute myocardial infarction, untreated severe valvular disease, or other major cardiovascular comorbidities were excluded. High-sensitivity cardiac troponin T (hs-cTnT), NT-proBNP, and soluble ST2 (sST2) were measured at baseline, during treatment, at therapy completion, and at late follow-up. Non-parametric tests were used for repeated-measures and subgroup comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant temporal variations were observed for all biomarkers. hs-cTnT increased from 5 [3\u20138] ng\/L at baseline to 15 [10\u201325] ng\/L at T2, while NT-proBNP increased from 120 [80\u2013190] pg\/mL to 210 [150\u2013320] pg\/mL. sST2 demonstrated a delayed elevation and remained increased at follow-up. Distinct biomarker patterns were observed across malignancy subgroups, with higher hs-cTnT increases in breast cancer, more prominent NT-proBNP elevation in lymphoma, and higher sST2 values in lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serial biomarker assessment may provide complementary information on myocardial injury, ventricular stress, and fibrotic remodeling during cancer therapy. The observed biomarker trajectories are suggestive of different biological processes involved in therapy-related cardiotoxicity, but they should be interpreted in conjunction with imaging findings and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-026-00538-3","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T23:14:27Z","timestamp":1783293267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal dynamics of cardiac biomarkers in therapy\u2011related cardiotoxicity: a prospective cardio\u2011oncology cohort study"],"prefix":"10.1186","volume":"12","author":[{"given":"Lidia Anca","family":"Kajanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana Lucia","family":"St\u0103nculeanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Chisoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Dobrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita-Cristina","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioan","family":"S\u00eerbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion Alexandru","family":"Popovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pundiche","family":"Mihaela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionut","family":"Bulbuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea Diana","family":"Kajanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"C\u00eempineanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Nelu\u021bu","family":"Mitroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgeta-Camelia","family":"Cozaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"13","key":"538_CR1","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.3390\/cancers16132419","volume":"16","author":"IM Sotiropoulou","year":"2024","unstructured":"Sotiropoulou IM, Manetas-Stavrakakis N, Kourek C, Xanthopoulos A, Magouliotis D, Giamouzis G, Skoularigis J, Briasoulis A. Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. Cancers. 2024;16(13):2419. https:\/\/doi.org\/10.3390\/cancers16132419.","journal-title":"Cancers"},{"key":"538_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40959-023-00159-0","volume":"9","author":"A Mir","year":"2023","unstructured":"Mir A, Badi Y, Bugazia S, et al. Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis. Cardio-Oncology. 2023;9:10. https:\/\/doi.org\/10.1186\/s40959-023-00159-0.","journal-title":"Cardio-Oncology"},{"issue":"8","key":"538_CR3","doi-asserted-by":"publisher","first-page":"e66258","DOI":"10.7759\/cureus.66258","volume":"16","author":"WN Hauwanga","year":"2024","unstructured":"Hauwanga WN, McBenedict B, Amadi ES, Dohadwala TK, Johnny C, Asaju F, Okafor OD, Jimoh A, Elumah AAO, Onyinyinyechi OV, Petrus D. Lima Pess\u00f4a B. A Systematic Review of the Cardiotoxic Effects of Targeted Therapies in Oncology. Cureus. 2024;16(8):e66258. https:\/\/doi.org\/10.7759\/cureus.66258 . PMID: 39238728; PMCID: PMC11377122.","journal-title":"Cureus"},{"key":"538_CR4","doi-asserted-by":"publisher","unstructured":"Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21\u201336. https:\/\/doi.org\/10.1007\/s10549-021-06280-x. Epub 2021 Jun 11. PMID: 34115243.","DOI":"10.1007\/s10549-021-06280-x"},{"key":"538_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/cells13171471","volume":"13","author":"VR Netala","year":"2024","unstructured":"Netala VR, Teertam SK, Li H, Zhang ZA. Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells. 2024;13:1471. https:\/\/doi.org\/10.3390\/cells13171471.","journal-title":"Cells"},{"issue":"36","key":"538_CR6","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Fernandez L, Mohty T, Piepoli D, Tamargo MF, Torbicki J, Suter A, ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211.","journal-title":"Eur Heart J"},{"key":"538_CR7","doi-asserted-by":"publisher","unstructured":"Lyon, A. R., L\u00f3pez-Fern\u00e1ndez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein,J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja,E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann,J., Lenihan, D., Moslehi, J., \u2026 ESC Scientific Document Group (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association(EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal. 43(41), 4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"538_CR8","doi-asserted-by":"publisher","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639-42. https:\/\/doi.org\/10.1038\/nm.2919. Epub 2012 Oct 28. PMID: 23104132.","DOI":"10.1038\/nm.2919"},{"key":"538_CR9","doi-asserted-by":"publisher","unstructured":"Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213-25. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.03.006. Epub 2012 Mar 21. PMID: 22465037.","DOI":"10.1016\/j.yjmcc.2012.03.006"},{"issue":"5","key":"538_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","volume":"5","author":"H Sawaya","year":"2012","unstructured":"Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596\u2013603. https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.973321. Epub 2012 Jun 28. PMID: 22744937; PMCID: PMC3703313.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"538_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.hfc.2022.02.003","volume":"18","author":"SS Scott","year":"2022","unstructured":"Scott SS, Greenlee AN, Matzko A, Stein M, Naughton MT, Zaramo TZ, Schwendeman EJ, Mohammad SJ, Diallo M, Revan R, Shimmin G, Tarun S, Ferrall J, Ho TH, Smith SA. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity. Heart Fail Clin. 2022;18(3):425\u201342. Epub 2022 Jun 1. PMID: 35718417; PMCID: PMC10391230.","journal-title":"Heart Fail Clin"},{"issue":"2","key":"538_CR12","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. https:\/\/doi.org\/10.1161\/JAHA.119.013757. Epub 2020 Jan 21. PMID: 31960755; PMCID: PMC7033840.","journal-title":"J Am Heart Assoc"},{"key":"538_CR13","doi-asserted-by":"crossref","unstructured":"Garrett Jensen X, Wang J, Kuempel N, Palaskas Z, Chen W, Yu Y, Chen H, Mohammad W, Luo, Jiang, Chang. Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review. Am J Physiol Heart Circ Physiol. 2025;328:4, H734\u201351.","DOI":"10.1152\/ajpheart.00687.2024"},{"key":"538_CR14","doi-asserted-by":"publisher","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalh\u00e3es A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911\u2009\u2013\u200939. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012. PMID: 25172399.","DOI":"10.1016\/j.echo.2014.07.012"},{"key":"538_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","volume":"9","author":"Y Zong","year":"2024","unstructured":"Zong Y, Li H, Liao P, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Sig Transduct Target Ther. 2024;9:124. https:\/\/doi.org\/10.1038\/s41392-024-01839-8.","journal-title":"Sig Transduct Target Ther"},{"key":"538_CR16","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/ijms26073218","volume":"26","author":"VR Netala","year":"2025","unstructured":"Netala VR, Hou T, Wang Y, Zhang Z, Teertam SK. Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis. Int J Mol Sci. 2025;26:3218. https:\/\/doi.org\/10.3390\/ijms26073218.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"538_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/biom14020199","volume":"14","author":"U Attanasio","year":"2024","unstructured":"Attanasio U, Di Sarro E, Tricarico L, et al. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond. Biomolecules. 2024;14(2):199. https:\/\/doi.org\/10.3390\/biom14020199. Published 2024 Feb 7.","journal-title":"Biomolecules"},{"key":"538_CR18","doi-asserted-by":"publisher","first-page":"1477679","DOI":"10.3389\/fcvm.2024.1477679","volume":"11","author":"C Chen","year":"2024","unstructured":"Chen C, Zheng H, Wang Y, Tong Y, Zhang H, Xie S, Ma X, Jiang M, Gong Z, Yan T, Tian Y, Guo L, Lu R. Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies. Front Cardiovasc Med. 2024;11:1477679. https:\/\/doi.org\/10.3389\/fcvm.2024.1477679.","journal-title":"Front Cardiovasc Med"},{"key":"538_CR19","doi-asserted-by":"publisher","first-page":"924461","DOI":"10.3389\/fcvm.2022.924461","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Chen Z, Ma M, He Y. Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance. Front Cardiovasc Med. 2022;9:924461. https:\/\/doi.org\/10.3389\/fcvm.2022.924461. PMID: 36225958; PMCID: PMC9548599.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"538_CR21","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/jcm12123970","volume":"12","author":"E Sciatti","year":"2023","unstructured":"Sciatti E, Merlo A, Scangiuzzi C, et al. Prognostic Value of sST2 in Heart Failure. J Clin Med. 2023;12(12):3970. https:\/\/doi.org\/10.3390\/jcm12123970. Published 2023 Jun 11.","journal-title":"J Clin Med"},{"issue":"5","key":"538_CR22","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00259-021-05341-z","volume":"48","author":"RHJA Slart","year":"2021","unstructured":"Slart RHJA, Williams MC, Juarez-Orozco LE, Rischpler C, Dweck MR, Glaudemans AWJM, Gimelli A, Georgoulias P, Gheysens O, Gaemperli O, Habib G, Hustinx R, Cosyns B, Verberne HJ, Hyafil F, Erba PA, Lubberink M, Slomka P, I\u0161gum I, Visvikis D, Kolossv\u00e1ry M, Saraste A. Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT\/CT, PET\/CT, and cardiac CT. Eur J Nucl Med Mol Imaging. 2021;48(5):1399\u2013413. https:\/\/doi.org\/10.1007\/s00259-021-05341-z. Epub 2021 Apr 17. PMID: 33864509; PMCID: PMC8113178.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"538_CR23","doi-asserted-by":"publisher","first-page":"20855","DOI":"10.18632\/oncotarget.25024","volume":"9","author":"Jolanta","year":"2018","unstructured":"Jolanta. Ma\u0142yszko1,2, Maciej Ma\u0142yszko1, Leszek Kozlowski3, Klaudia Kozlowska1 and Jacek Ma\u0142yszko. Hypertension in malignancy\u2013an underappreciated problem. Oncotarget. 2018;9:20855\u201371. https:\/\/doi.org\/10.18632\/oncotarget.25024.","journal-title":"Oncotarget"},{"issue":"6","key":"538_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/eurjpc\/zwaa034","volume":"29","author":"J Caro-Cod\u00f3n","year":"2022","unstructured":"Caro-Cod\u00f3n J, L\u00f3pez-Fern\u00e1ndez T, \u00c1lvarez-Ortega C, et al. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol. 2022;29(6):859\u201368. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa034.","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"538_CR25","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1177\/2047487320943002","volume":"28","author":"A Guha","year":"2021","unstructured":"Guha A, Desai NR, Weintraub NL. Assessing cardiovascular risk in cancer patients: opportunities and challenges. Eur J Prev Cardiol. 2021;28(9):e45\u20136. https:\/\/doi.org\/10.1177\/2047487320943002.","journal-title":"Eur J Prev Cardiol"},{"key":"538_CR26","doi-asserted-by":"publisher","unstructured":"Melissa Bolier, Vincent G, Pluimakers, Demi TC, de Winter M, Fiocco, Sjoerd AA, van den Berg GO, Janssens, Leontien CM, Kremer JJ, Loonen M, Louwerens, Helena J, van der Pal, Saskia MF, Pluijm, Wim JE, Tissing, Hanneke M, van Santen, Andrica CH, de Vries. Aart-Jan van der Lely, Marry M van den Heuvel-Eibrink, Sebastian J C M M Neggers, Prevalence and determinants of dyslipidemia in 2338 Dutch childhood cancer survivors: a DCCS-LATER 2 study, European Journal of Endocrinology, Volume 191, Issue 6, December 2024, Pages 588\u2013603. https:\/\/doi.org\/10.1093\/ejendo\/lvae149.","DOI":"10.1093\/ejendo\/lvae149"},{"key":"538_CR27","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/ph18091399","volume":"18","author":"G Ciappina","year":"2025","unstructured":"Ciappina G, Colarusso L, Maiorana E, Ottaiano A, Franchina T, Picone A, Facchini G, Barraco C, Ieni A, Cusm\u00e0 Piccione M, et al. Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice. Pharmaceuticals. 2025;18:1399. https:\/\/doi.org\/10.3390\/ph18091399.","journal-title":"Pharmaceuticals"},{"key":"538_CR28","doi-asserted-by":"publisher","unstructured":"Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, Marwick TH. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023;16(3):269\u2013278. 10.1016\/j.jcmg.2022.10.010. Epub 2022 Nov 16. PMID: 36435732. https:\/\/doi.org\/10.1016\/j.jcmg.2022.10.010.","DOI":"10.1016\/j.jcmg.2022.10.010"},{"key":"538_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM. ICOS-ONE Study Investigators. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.005. Epub 2018 Mar 20. PMID: 29567630.","journal-title":"Eur J Cancer"},{"issue":"22","key":"538_CR30","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749\u201354. Epub 2004 May 17. PMID: 15148277.","journal-title":"Circulation"},{"key":"538_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. https:\/\/doi.org\/10.3389\/fcvm.2020.00026.","journal-title":"Front Cardiovasc Med"},{"issue":"23","key":"538_CR32","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Dom\u00e8nech A, Ortiz-P\u00e9rez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monz\u00f3 M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.072.","journal-title":"J Am Coll Cardiol"},{"key":"538_CR33","doi-asserted-by":"publisher","unstructured":"Hinrichs L, Mrotzek SM, Mincu RI, Pohl J, R\u00f6ll A, Michel L, Mahabadi AA, Al-Rashid F, Totzeck M, Rassaf T, PMCID. Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry. Front Pharmacol. 2020;11:740. https:\/\/doi.org\/10.3389\/fphar.2020.00740. PMID: 32508657; : PMC7248256. https:\/\/www","DOI":"10.3389\/fphar.2020.00740"},{"issue":"4","key":"538_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiography: official publication Am Soc Echocardiography. 2016;29(4):277\u2013314. https:\/\/doi.org\/10.1016\/j.echo.2016.01.011.","journal-title":"J Am Soc Echocardiography: official publication Am Soc Echocardiography"},{"key":"538_CR35","doi-asserted-by":"publisher","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalh\u00e3es A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911\u2009\u2013\u200939. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012. PMID: 25172399.","DOI":"10.1016\/j.echo.2014.07.012"},{"issue":"5","key":"538_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jchf.2020.03.003","volume":"8","author":"JL Januzzi Jr","year":"2020","unstructured":"Januzzi JL Jr, Myhre PL. The Challenges of NT-proBNP Testing in HFpEF: Shooting Arrows in the Wind. JACC Heart Fail. 2020;8(5):382\u20135. https:\/\/doi.org\/10.1016\/j.jchf.2020.03.003.","journal-title":"JACC Heart Fail"},{"key":"538_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/CPAA.S256290","volume":"12","author":"N Firouzabadi","year":"2020","unstructured":"Firouzabadi N, Dashti M, Dehshahri A, Bahramali E. Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure. Clin Pharmacol. 2020;12:53\u20138. https:\/\/doi.org\/10.2147\/CPAA.S256290. Published 2020 Jun 12.","journal-title":"Clin Pharmacol"},{"key":"538_CR38","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1038\/s41598-021-82745-9","volume":"11","author":"MC Asensio-Lopez","year":"2021","unstructured":"Asensio-Lopez MC, Sassi Y, Soler F, et al. The miRNA199a\/SIRT1\/P300\/Yy1\/sST2 signaling axis regulates adverse cardiac remodeling following MI. Sci Rep. 2021;11:3915. https:\/\/doi.org\/10.1038\/s41598-021-82745-9.","journal-title":"Sci Rep"},{"issue":"1","key":"538_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/biomedicines13010060","volume":"13","author":"M Dudek","year":"2025","unstructured":"Dudek M, Ka\u0142u\u017cna-Oleksy M, Sawczak F, Kukfisz A, Soloch A, Migaj J, Lesiak M, Straburzy\u0144ska-Migaj E. The Usefulness of Soluble ST2 Concentration in Heart Failure with Reduced Ejection Fraction to Predict Severe Impairment in Exercise Capacity Assessed in Cardiopulmonary Exercise Testing. Biomedicines. 2025;13(1):60. https:\/\/doi.org\/10.3390\/biomedicines13010060.","journal-title":"Biomedicines"},{"key":"538_CR40","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s40001-025-02874-z","volume":"30","author":"Q Wu","year":"2025","unstructured":"Wu Q, Zheng X, Lin X, et al. Predictive role of serum sST2 for heart failure in children with severe pneumonia. Eur J Med Res. 2025;30:593. https:\/\/doi.org\/10.1186\/s40001-025-02874-z.","journal-title":"Eur J Med Res"},{"issue":"8","key":"538_CR41","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/diagnostics15081010","volume":"15","author":"F Davini","year":"2025","unstructured":"Davini F, Fogolari M, D\u2019Avanzo G, Ristori MV, Nucciarelli S, Bani L, Cristiano A, De Cesaris M, Spoto S, Angeletti S. Soluble Suppression of Tumorigenicity 2 (sST2) as a Diagnostic and Prognostic Marker in Acute Heart Failure and Sepsis: A Comparative Analysis. Diagnostics. 2025;15(8):1010. https:\/\/doi.org\/10.3390\/diagnostics15081010.","journal-title":"Diagnostics"},{"issue":"41","key":"538_CR42","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"2","key":"538_CR43","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/49.2.248","volume":"49","author":"MT Sandri","year":"2003","unstructured":"Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49(2):248\u201352. https:\/\/doi.org\/10.1373\/49.2.248.","journal-title":"Clin Chem"},{"issue":"9","key":"538_CR44","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","volume":"107","author":"H Sawaya","year":"2011","unstructured":"Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375\u201380. https:\/\/doi.org\/10.1016\/j.amjcard.2011.01.006.","journal-title":"Am J Cardiol"},{"issue":"20","key":"538_CR45","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.006","volume":"70","author":"D Cardinale","year":"2017","unstructured":"Cardinale D, Biasillo G, Salvatici M, Sandri MT, Cipolla CM. Using biomarkers to predict and prevent cardiotoxicity of cancer therapy. J Am Coll Cardiol. 2017;70(20):2552\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.006.","journal-title":"J Am Coll Cardiol"},{"key":"538_CR46","doi-asserted-by":"publisher","first-page":"653648","DOI":"10.3389\/fcvm.2021.653648","volume":"8","author":"G Macnaught","year":"2021","unstructured":"Macnaught G, Oikonomidou O, Rodgers CT, Clarke W, Cooper A, McVicars H, Hayward L, Mirsadraee S, Semple S, Denvir MA. Cardiac Energetics Before, During, and After Anthracycline-Based Chemotherapy in Breast Cancer Patients Using 31P Magnetic Resonance Spectroscopy: A Pilot Study. Front Cardiovasc Med. 2021;8:653648. https:\/\/doi.org\/10.3389\/fcvm.2021.653648.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"538_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clon.2019.11.008","volume":"32","author":"E Tzolos","year":"2020","unstructured":"Tzolos E, Adamson PD, Hall PS, et al. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy. Clin Oncol (R Coll Radiol). 2020;32(5):292\u20137. https:\/\/doi.org\/10.1016\/j.clon.2019.11.008.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"538_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/MS9.0000000000002753","volume":"87","author":"NA Ahmed","year":"2025","unstructured":"Ahmed NA, Redwan FN, Jahjah AS, Al-Shehabi ZA. Evaluating high-sensitivity cardiac troponin I for early detection of treatment-related cardiotoxicity in HER2-positive breast cancer patients. Ann Med Surg (Lond). 2025;87(1):93\u2013102. https:\/\/doi.org\/10.1097\/MS9.0000000000002753. Published 2025 Jan 9.","journal-title":"Ann Med Surg (Lond)"},{"issue":"3","key":"538_CR49","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jamacardio.2022.5309","volume":"8","author":"X Jia","year":"2023","unstructured":"Jia X, Al Rifai M, Hoogeveen R, et al. Association of Long-term Change in N-Terminal Pro\u2013B-Type Natriuretic Peptide With Incident Heart Failure and Death. JAMA Cardiol. 2023;8(3):222\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2022.5309.","journal-title":"JAMA Cardiol"},{"issue":"10","key":"538_CR50","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCULATIONAHA.120.050561","volume":"143","author":"B Ky","year":"2021","unstructured":"Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Circulation. 2021;143(10):1021\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050561.","journal-title":"Circulation"},{"issue":"6","key":"538_CR51","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/jpm12060890","volume":"12","author":"LN Ghilencea","year":"2022","unstructured":"Ghilencea LN, Bejan GC, Zamfirescu MB, et al. B-Type Natriuretic Peptide at Admission Is a Predictor of All-Cause Mortality at One Year after the First Acute Episode of New-Onset Heart Failure with Preserved Ejection Fraction. J Pers Med. 2022;12(6):890. https:\/\/doi.org\/10.3390\/jpm12060890. Published 2022 May 28.","journal-title":"J Pers Med"},{"issue":"2","key":"538_CR52","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/ehjci\/jeab259","volume":"23","author":"A Koutsoukis","year":"2022","unstructured":"Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevaidis I. Cardio-oncology: a focus on cardiotoxicity. Eur Heart J \u2013 Cardiovasc Imaging. 2022;23(2):e1\u201313. https:\/\/doi.org\/10.1093\/ehjci\/jeab259.","journal-title":"Eur Heart J \u2013 Cardiovasc Imaging"},{"key":"538_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.breast.2020.09.001","volume":"54","author":"I Blancas","year":"2020","unstructured":"Blancas I, Mart\u00edn-P\u00e9rez FJ, Garrido JM, Rodr\u00edguez-Serrano F. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast. 2020;54:106\u201313. https:\/\/doi.org\/10.1016\/j.breast.2020.09.001.","journal-title":"Breast"},{"key":"538_CR54","doi-asserted-by":"publisher","unstructured":"Lars Michel RI, Mincu AA, Mahabadi S, Settelmeier F, Al-Rashid T, Rassaf M, Totzeck. Troponins and Brain Natriuretic Peptides for the Prediction of Cardiotoxicity in Cancer Patients: A Meta-Analysis. Eur J Heart Fail. February 2020;22(2):350\u201361. https:\/\/doi.org\/10.1002\/ejhf.1631.","DOI":"10.1002\/ejhf.1631"},{"issue":"10","key":"538_CR55","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jchf.2020.06.011","volume":"8","author":"JL Januzzi","year":"2020","unstructured":"Januzzi JL, Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, et al. ST2 and adverse remodeling in heart failure. JACC: Heart Fail. 2020;8(10):818\u201328. https:\/\/doi.org\/10.1016\/j.jchf.2020.06.011.","journal-title":"JACC: Heart Fail"},{"key":"538_CR56","doi-asserted-by":"publisher","unstructured":"Camilli M, Cipolla C, Dent S, et al. Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review. J Am Coll Cardiol CardioOnc. 2024 Oct;6(5):655\u201377. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.016.","DOI":"10.1016\/j.jaccao.2024.07.016"},{"issue":"16","key":"538_CR57","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","volume":"129","author":"FA van Nimwegen","year":"2017","unstructured":"van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, Janus CPM, Daniels L, van Leeuwen FE, Cutter DJ, Aleman BMP. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257\u201365. https:\/\/doi.org\/10.1182\/blood-2016-09-740332 . Epub 2017 Jan 31. PMID: 28143884; PMCID: PMC5418626.","journal-title":"Blood"},{"key":"538_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40959-024-00222-4","volume":"10","author":"AW Bjerring","year":"2024","unstructured":"Bjerring AW, Smeland KH, Stokke T, et al. Long-term cardiac effects of modern treatment for Hodgkin\u2019s lymphoma. Cardio-Oncology. 2024;10:19. https:\/\/doi.org\/10.1186\/s40959-024-00222-4.","journal-title":"Cardio-Oncology"},{"issue":"16","key":"538_CR59","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMra2105052","volume":"385","author":"J Moslehi","year":"2021","unstructured":"Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN, Dudley JT, et al. Immune checkpoint inhibitor\u2013associated myocarditis. N Engl J Med. 2021;385(16):1522\u201334. https:\/\/doi.org\/10.1056\/NEJMra2105052.","journal-title":"N Engl J Med"},{"key":"538_CR60","doi-asserted-by":"publisher","unstructured":"Januzzi JL, Pascual-Figal D, Daniels LB. ST2 Testing for Chronic Heart Failure Therapy Monitoring: The International ST2 Consensus Panel,The American Journal of Cardiology,115, Issue 7, Supplement, 2015, Pages 70B-75B, ISSN 0002-9149, https:\/\/doi.org\/10.1016\/j.amjcard.2015.01.044.","DOI":"10.1016\/j.amjcard.2015.01.044"},{"key":"538_CR61","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","volume":"74","author":"A Aimo","year":"2019","unstructured":"Aimo A, Januzzi JL, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C. Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74:2193\u2013203. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1039.","journal-title":"J Am Coll Cardiol"},{"key":"538_CR62","doi-asserted-by":"publisher","first-page":"117954681984280","DOI":"10.1177\/1179546819842804","volume":"13","author":"M Kercheva","year":"2019","unstructured":"Kercheva M, Ryabova T, Gusakova A, Suslova TE, Ryabov V, Karpov RS. Serum Soluble ST2 and Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction. Clin Med Insights Cardiol. 2019;13:1179546819842804. https:\/\/doi.org\/10.1177\/1179546819842804. Published 2019 Apr 24.","journal-title":"Clin Med Insights Cardiol"},{"key":"538_CR63","doi-asserted-by":"publisher","first-page":"1426796","DOI":"10.3389\/fonc.2024.1426796","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Qiu Q, Deng X, Wan M. EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring. Front Oncol. 2024;14:1426796. https:\/\/doi.org\/10.3389\/fonc.2024.1426796. Published 2024 Jun 24.","journal-title":"Front Oncol"},{"key":"538_CR64","doi-asserted-by":"publisher","first-page":"100575","DOI":"10.1016\/j.cophys.2022.100575","volume":"29","author":"RRS Packard","year":"2022","unstructured":"Packard RRS. Cardiac fibrosis in oncologic therapies. Curr Opin Physiol. 2022;29:100575. https:\/\/doi.org\/10.1016\/j.cophys.2022.100575.","journal-title":"Curr Opin Physiol"},{"issue":"1","key":"538_CR65","doi-asserted-by":"publisher","first-page":"2512645","DOI":"10.1080\/21645515.2025.2512645","volume":"21","author":"L Xu","year":"2025","unstructured":"Xu L, Chen Y, Xiong L, et al. A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers. Hum Vaccin Immunother. 2025;21(1):2512645. https:\/\/doi.org\/10.1080\/21645515.2025.2512645.","journal-title":"Hum Vaccin Immunother"},{"key":"538_CR66","doi-asserted-by":"publisher","unstructured":"Bernd JW, Calvillo-Arg\u00fcelles O, Lheureux S, Houbois CP, Spreafico A, Bedard PL, Neilan TG, Thavendiranathan P. Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria. Eur Heart J - Case Rep. January 2022;6(1):ytab478. https:\/\/doi.org\/10.1093\/ehjcr\/ytab478.","DOI":"10.1093\/ehjcr\/ytab478"},{"key":"538_CR67","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1002\/cai2.109","volume":"3","author":"W Song","year":"2024","unstructured":"Song W, Zhang N, Lv T, Zhao Y, Li G, Tse G, et al. Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis: a systematic review and meta\u2010analysis. Cancer Innov. 2024;3:e109. https:\/\/doi.org\/10.1002\/cai2.109.","journal-title":"Cancer Innov"},{"key":"538_CR68","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, Ky B, \u0160t\u011brba M, Cardinale D, Cohen-Solal A, Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P, Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot J-S, Skouri H, H\u00e4gler-Laube ES, Asteggiano R, Fernandez TL, de Boer RA, Lyon AR. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966\u201383. https:\/\/doi.org\/10.1002\/ejhf.2017.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"538_CR69","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","volume":"6","author":"BC Drafts","year":"2013","unstructured":"Drafts BC, Twomley KM, D\u2019Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6(8):877\u201385. Epub 2013 May 1. PMID: 23643285; PMCID: PMC3745801.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"25 Pt A","key":"538_CR70","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.073.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"538_CR71","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jcmg.2022.06.016","volume":"16","author":"T Negishi","year":"2023","unstructured":"Negishi T, Thavendiranathan P, Marwick TH, et al. Three-Year Outcomes of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes (SUCCOUR) Trial. JACC Cardiovasc Imaging. 2023;16(3):348\u201358. https:\/\/doi.org\/10.1016\/j.jcmg.2022.06.016.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"538_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12471-022-01734-3","volume":"31","author":"D van der Linde","year":"2023","unstructured":"van der Linde D, van Hagen I, Veen K, Zuetenhorst H, van Dalen B. Global longitudinal strain: an early marker for cardiotoxicity in patients treated for breast cancer. Neth Heart J. 2023;31(3):103\u20138. https:\/\/doi.org\/10.1007\/s12471-022-01734-3.","journal-title":"Neth Heart J"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00538-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00538-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00538-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:27:12Z","timestamp":1786602432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00538-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["538"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00538-3","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the \u201cProf. Dr. Alexandru Trestioreanu\u201d Oncology Institute, Bucharest, Romania. The research was conducted in accordance with the principles of the Declaration of Helsinki (2013 revision) and applicable European regulations on biomedical research involving human subjects.Written informed consent was obtained from all participants prior to enrollment in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"107"}}